---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-024350"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:58:51.295238+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PepGen gets UK MHRA clearance to start Phase 2 trial of PGN-EDO51 for DMD

## Summary
- MHRA authorized CTA for CONNECT2-EDO51 Phase 2 trial of PGN-EDO51 in DMD patients amenable to exon 51 skipping.
- Trial is randomized, placebo-controlled, multiple ascending dose, enrolling ~20 boys/young men aged ≥6 years.
- PGN-EDO51 is an oligonucleotide therapy; data from CONNECT1 (ongoing Phase 1) plus CONNECT2 could support accelerated approval.
- Starting dose 5 mg/kg escalating to 10 mg/kg and potentially higher; muscle biopsies at baseline and week 25 to assess exon skipping and dystrophin production.
- Participants have option for open-label extension after 24-week treatment period.

## SEC filing metadata
- accession: 0000950170-24-024350
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017024024350/0000950170-24-024350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017024024350/pepg-20240304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-024350
- JSON: https://secwatch.observer/filing/0000950170-24-024350.json
- Plain text: https://secwatch.observer/filing/0000950170-24-024350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.